Login to Your Account


Pharma: Other News To Note


Wednesday, February 20, 2013
• Novartis AG, of Basel, Switzerland, said the FDA approved mTOR inhibitor Zortress (everolimus) for the prophylaxis of organ rejection in adults receiving liver transplants.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription


»

For Sales Inquiries,
http://clarivate.com/life-sciences/news/bioworld/#

NORTH AMERICA
Tel: +1-855-260-5607
Outside of the US
Tel. +44-203-684-1797
 
Privacy Policy | Terms of Use | Copyright
 
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2017 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Clarivate Analytics